Diabetes, Vol 37, Issue 9 1234-1240, Copyright © 1988 by American Diabetes Association
Insulin-mimetic effects of vanadate in primary cultures of rat hepatocytes
TK Jackson, AI Salhanick, JD Sparks, CE Sparks, M Bolognino and JM Amatruda
Department of Medicine, University of Rochester School of Medicine and Dentistry, New York.
To evaluate possible mechanisms by which insulin inhibits hepatic
apolipoprotein B (apoB) secretion, we incubated primary cultures of rat
hepatocytes with sodium orthovanadate, a phosphotyrosine phosphatase
inhibitor and insulin-mimetic agent. Vanadate (10 microM) and insulin (10
nM) inhibited the medium accumulation of apoB (secretion) by 21 and 37%,
respectively, without increasing intracellular apoB. The effects of insulin
and vanadate together were not additive. Both insulin and vanadate enhanced
intracellular glycogen accumulation by 82 and 37%, respectively. Unlike
insulin, vanadate, at a concentration that inhibited apoB secretion (10
microM), had no effect on intracellular lipogenesis, inhibited the
secretion of newly synthesized hepatic proteins, and had a delayed onset
and termination of action on inhibition of apoB secretion. At higher
concentrations (40 and 80 microM), vanadate stimulated intracellular
lipogenesis. In conclusion, our data indicate that vanadate mimics insulin
action in hepatocytes with regard to the inhibition of medium accumulation
of apoB. These data are consistent with the hypothesis that inhibition of
apoB secretion may be secondary to an increase in phosphotyrosine content
at its site of synthesis. The kinases responsible for this effect have not
been identified. Several effects of vanadate, however, are different from
those of insulin, suggesting a differential sensitivity to vanadate, a
divergence of the signal transfer by insulin and vanadate at the
insulin-receptor or postreceptor level, or both.